Airain Ltd’s Arbutus Biopharma ABUS Stock Holding History

Airain Ltd’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-20,582	Closed	-$92K	–	767
2015 Q4	$92K	Buy	20,582 +1,447	+8%	+$7.93K	0.01%	774
2015 Q3	$117K	Buy	+19,135	New	+$170K	0.01%	760

Other funds holding ABUS

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Airain Ltd's ABUS Position: Q1 2016 in Review

Airain Ltd sold out of Arbutus Biopharma (ABUS) in Q1 2016, closing a stake of 20,582 shares — an estimated $92K sold.

Airain Ltd first reported a position in ABUS in Q3 2015 and held it in 2 quarters. The position peaked at $117K in Q3 2015. 49 funds tracked by Wall St. Rank hold ABUS as of Q1 2016.

Airain Ltd reported no remaining Arbutus Biopharma position as of Q1 2016 after selling out during the quarter.
Airain Ltd sold 20,582 Arbutus Biopharma shares in Q1 2016, an estimated $92K.
Airain Ltd first reported a position in Arbutus Biopharma in Q3 2015 and held it in 2 quarters.
Airain Ltd's Arbutus Biopharma position peaked at $117K in Q3 2015.
49 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2016.

Based on Airain Ltd's 13F filing for Q1 2016, filed 9 May 2016.